Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06980948 | Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) | PHASE1 | RECRUITING | 27 | — | — | Dec 4, 2025 | Jul 1, 2028 | Jun 1, 2026 | 11 | United States |
To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.
| Arm | Type | Description |
|---|---|---|
| Sham Controlled Study | SHAM_COMPARATOR | - |
| Investigational Agent | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ST-503 | GENETIC | Genomic Medicine |
| Sham (No Treatment) | PROCEDURE | Sham Procedure |
Inclusion Criteria 1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria. 2. Medical record documentation that pain is refractory to 2 of 3 categori...